Macquarie Begins Coverage on Genomic Health, Myriad Genetics | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Macquarie Capital today initiated coverage on five clinical laboratories, which included molecular diagnostics firms Genomic Health and Myriad Genetics.

The investment firm also began covering Bio-Reference Laboratories, Laboratory Corporation of America, and Quest Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.